Compare · ABT vs NUVL
ABT vs NUVL
Side-by-side comparison of Abbott Laboratories (ABT) and Nuvalent Inc. (NUVL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and NUVL operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT carries a market cap of $178.38B.
- Over the past year, ABT is down 19.5% and NUVL is up 17.1% - NUVL leads by 36.6 points.
- ABT has been more active in the news (11 items in the past 4 weeks vs 2 for NUVL).
- Both have 25 recent analyst ratings on file.
- Company
- Abbott Laboratories
- Nuvalent Inc.
- Price
- $103.18-0.75%
- -
- Market cap
- $178.38B
- -
- 1M return
- +0.63%
- +0.46%
- 1Y return
- -19.52%
- +17.09%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 11
- 2
- Recent ratings
- 25
- 25
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Nuvalent Inc.
Nuvalent, Inc., a preclinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor, designed to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors; and NVL-655, a brain-penetrant ALK-selective inhibitor, designed to inhibit ALK fusions that express the normal ALK kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to first, second, and third generation ALK inhibitors. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Latest ABT
- Abbott initiates VOYAGER clinical trial for investigational Encantor™ software-guided balloon-expandable TAVI system to treat aortic stenosis
- Abbott Labs upgraded by Leerink Partners with a new price target
- Abbott Laboratories filed SEC Form 8-K: Leadership Update
- New Abbott Panbio™ COVID-19/Flu A&B Self-Test Helps Canadian Families Make Informed Decisions During Respiratory Illness Season
- EXECUTIVE VICE PRESIDENT Moreland Mary K sold $406,000 worth of Common shares without par value (3,500 units at $116.00), decreasing direct ownership by 3% to 100,791 units (SEC Form 4)
- SEC Form 10-Q filed by Abbott Laboratories
- Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke
- Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System
- Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease
- Abbott Labs downgraded by Argus
Latest NUVL
- FDA Approval for NELKARMI issued to NUVALENT
- FDA Approval for NELKARMI issued to NUVALENT
- SEC Form 15-12G filed by Nuvalent Inc.
- FDA Approval for JIDEYTRO issued to NUVALENT INC
- Amendment: SEC Form SCHEDULE 13G/A filed by Nuvalent Inc.
- Director by Deputization Flynn James E returned $427,056 worth of Class A Common Stock - Restricted Stock Units to the company (3,444 units at $124.00) and returned $2,138,807,800 worth of shares to the company (17,248,450 units at $124.00) (SEC Form 4) to satisfy withholding tax
- Director Meyers Michael L. returned 3,444 units of Class A Common Stock - Restricted Stock Units to the company, closing all direct ownership in the company (SEC Form 4) to cover taxes
- Chief Financial Officer Balcom Alexandra returned 41,100 units of Class A Common Stock - Restricted Stock Units to the company, was granted 14,350 units of Class A Common Stock - Performance Stock Units and returned 14,350 units of Class A Common Stock - Performance Stock Units to the company, closing all direct ownership in the company (SEC Form 4) to satisfy withholding tax
- Director Srivastava Sapna returned 3,444 units of Class A Common Stock - Restricted Stock Units to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)
- Director Oliger Christy J. returned 6,091 units of Class A Common Stock - Restricted Stock Units to the company, closing all direct ownership in the company (SEC Form 4) (tax liability)